Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
Moodys
Citi
Chinese Patent Office
Merck
Deloitte
Johnson and Johnson
Argus Health

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,974,861

« Back to Dashboard

Summary for Patent: 6,974,861
Title: Pharmaceutical compositions and methods using natriuretic peptides
Abstract:The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: wherein R.sup.1 is selected from the group consisting of: or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof; R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) is and R.sup.1 is Asp-Ser-Gly-, R.sup.2 cannot be Asn-Val-Leu-Arg-Arg-Tyr. The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.
Inventor(s): Seilhamer; J. Jeffrey (Milpitas, CA), Lewicki; John (San Jose, CA), Scarborough; Robert M. (Hayward, CA), Porter; J. Gordon (Newark, CA)
Assignee: Scios, Inc. (Sunnyvale, CA)
Application Number:10/402,021
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 6,974,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,974,861

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 68923878 ➤ Try a Free Trial
Japan H03505280 ➤ Try a Free Trial
Ireland 68889 ➤ Try a Free Trial
Ireland 891792 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Moodys
Teva
McKesson
Federal Trade Commission
Fuji
Cantor Fitzgerald
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.